China Sets Norms For Foreign Trial Data Submissions

China's latest draft rules set conditions for accepting foreign clinical study data, discouraging ‘selective filing’. Experts see enhanced opportunities for international drug makers to register new products, especially drugs to treat critical, pediatric and rare diseases.